Ads
related to: cancer immunotherapy companyexplorefrog.com has been visited by 10K+ users in the past month
assistantsage.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.
The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. [1] The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2]
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect ...
The company's lead programme targets glioblastoma (GBM), the most aggressive form of brain cancer, where only 25% of patients survive beyond one year. Preclinical studies have demonstrated curative responses with no toxicity and evidence of persistent anti-tumour immunity, with Phase 1/2 clinical trials planned for 2025.
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park . [ 1 ] In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra , a therapy against a rare form of cancer.
Ads
related to: cancer immunotherapy companyexplorefrog.com has been visited by 10K+ users in the past month
assistantsage.com has been visited by 10K+ users in the past month